L Petrone1, A Cannas1, V Vanini1, G Cuzzi1, F Aloi2, M Nsubuga3, J Sserunkuma3, R A Nazziwa3, L Jugheli4, T Lukindo5, E Girardi6, A Antinori7, L Pucci8, K Reither9, D Goletti1. 1. Translational Research Unit, Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases (INMI), Rome, Italy. 2. Italian Association for Solidarity Among People, Kampala, St Francis Nsambya Hospital, Kampala, Uganda. 3. St Francis Nsambya Hospital, Kampala, Uganda. 4. Medical Services and Diagnostic Department, Swiss Tropical and Public Health Institute, Basel, Switzerland. 5. Ifakara Health Institute, Bagamoyo Research and Training Center, Bagamoyo, United Republic of Tanzania. 6. Department of Epidemiology and Preclinical Research, Rome, Italy. 7. Clinical Department, INMI, Rome, Italy. 8. Clinical Biochemistry and Pharmacology Laboratory, INMI, Rome, Italy. 9. Medical Services and Diagnostic Department, Swiss Tropical and Public Health Institute, Basel, University of Basel, Basel, Switzerland; Ifakara Health Institute, Bagamoyo Research and Training Center, Bagamoyo, United Republic of Tanzania.
Abstract
SETTING: Blood interferon-γ inducible protein 10 (IP-10) has been proposed as a biomarker of disease activity for both tuberculosis (TB) and human immunodeficiency virus (HIV) infection. Urine IP-10 has been detected in adults with active TB, and its level decreases after successful anti-tuberculosis treatment. OBJECTIVE: To evaluate blood and urine IP-10 as biomarker of disease activity. DESIGN: Patients with HIV-TB and active TB were enrolled. Individuals with HIV infection only and healthy donors were included as controls. Blood and urine IP-10 levels were measured using an enzyme-linked immunosorbent assay. RESULTS: Of 39 active TB patients enrolled, 24 were HIV-infected and 15 were HIV-uninfected. Of 87 control subjects without active TB, 54 were HIV-infected and 33 were HIV-uninfected. IP-10 analysis was performed in patients with concomitant blood and urine sample collection. Blood IP-10 was associated with active TB, regardless of HIV infection status; urine IP-10 levels were increased in active TB patients, although the difference was significant in HIV-infected individuals only. Finally, in HIV-infected patients, both blood and urine IP-10 levels were inversely correlated with CD4 T-cell counts. CONCLUSION: These findings suggest that IP-10 could be used as a biomarker for disease activity (inflammation).
SETTING: Blood interferon-γ inducible protein 10 (IP-10) has been proposed as a biomarker of disease activity for both tuberculosis (TB) and human immunodeficiency virus (HIV) infection. Urine IP-10 has been detected in adults with active TB, and its level decreases after successful anti-tuberculosis treatment. OBJECTIVE: To evaluate blood and urine IP-10 as biomarker of disease activity. DESIGN:Patients with HIV-TB and active TB were enrolled. Individuals with HIV infection only and healthy donors were included as controls. Blood and urine IP-10 levels were measured using an enzyme-linked immunosorbent assay. RESULTS: Of 39 active TB patients enrolled, 24 were HIV-infected and 15 were HIV-uninfected. Of 87 control subjects without active TB, 54 were HIV-infected and 33 were HIV-uninfected. IP-10 analysis was performed in patients with concomitant blood and urine sample collection. Blood IP-10 was associated with active TB, regardless of HIV infection status; urine IP-10 levels were increased in active TB patients, although the difference was significant in HIV-infected individuals only. Finally, in HIV-infectedpatients, both blood and urine IP-10 levels were inversely correlated with CD4 T-cell counts. CONCLUSION: These findings suggest that IP-10 could be used as a biomarker for disease activity (inflammation).
Authors: Alberto L García-Basteiro; Edson Mambuque; Alice den Hertog; Belén Saavedra; Inocencia Cuamba; Laura Oliveras; Silvia Blanco; Helder Bulo; Joe Brew; Luis E Cuevas; Frank Cobelens; Augusto Nhabomba; Richard Anthony Journal: Sci Rep Date: 2017-10-30 Impact factor: 4.379
Authors: Stephen D Lawn; Andrew D Kerkhoff; Rosie Burton; Charlotte Schutz; Andrew Boulle; Monica Vogt; Ankur Gupta-Wright; Mark P Nicol; Graeme Meintjes Journal: BMC Med Date: 2017-03-21 Impact factor: 8.775
Authors: Elisa Petruccioli; Thomas J Scriba; Linda Petrone; Mark Hatherill; Daniela M Cirillo; Simone A Joosten; Tom H Ottenhoff; Claudia M Denkinger; Delia Goletti Journal: Eur Respir J Date: 2016-11-11 Impact factor: 16.671
Authors: Rosalie Lubbers; Jayne S Sutherland; Delia Goletti; Roelof A de Paus; Coline H M van Moorsel; Marcel Veltkamp; Stefan M T Vestjens; Willem J W Bos; Linda Petrone; Franca Del Nonno; Ingeborg M Bajema; Karin Dijkman; Frank A W Verreck; Gerhard Walzl; Kyra A Gelderman; Geert H Groeneveld; Annemieke Geluk; Tom H M Ottenhoff; Simone A Joosten; Leendert A Trouw Journal: Front Immunol Date: 2018-10-23 Impact factor: 7.561